Replies to post #127349 on Biotech Values

[bellweather1]

Peter,

But don't you assume, that 1)if Ponatinib is demonstrated to be clearly superior in a head to head trial(becoming 1st line),

and 2)that it's greatest efficacy long-term continues to result from earliest initiation,

that most(if not all) insurances will be forced to reimburse for it, regardless of cost pressures?

If 1&2, would Gleevec and others all then be relegated to 2nd line?

Thanks, and
Regards,

bw